Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Can you use a 401(k) to buy gold? What investors should know before rolling over retirement funds

A 401(k) can provide a path to gold investing, but the process — and the risks — require careful consideration.

The volatile gold market has made many retirement investors contemplate how to incorporate the precious metal into their retirement strategy. While gold may offer some portfolio diversification benefits, using a traditional 401(k) to directly purchase gold is not always straightforward. Most workplace retirement plans offer a preset list of investments, which typically does not include physical gold. However, there are alternative ways to gain exposure to gold within a retirement account.

One potential option is to roll funds from the existing 401(k) into a self-directed individual retirement account (IRA) that allows for alternative investments, like precious metals. Self-directed IRAs can hold a wider range of assets than standard IRAs, including certain types of gold. However, the IRS has strict rules about what constitutes eligible gold investments, such as requiring the gold to be in the form of specific bullion or coins.

Additionally, a custodian must manage the account, and there are rules about how the gold must be stored.

Before initiating a rollover, it's important to determine if the 401(k) allows for distributions to be moved into an IRA. Typically, this can be done without triggering immediate taxes or penalties. However, if the funds are taken directly from the 401(k), the process becomes more complex. Qualified distributions must be rolled over within 60 days, and a 20% withholding tax is usually applied to avoid early withdrawal penalties.

Written by urgent.news from CBS News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at cbsnews.com →

More in Finance & Markets

Why is United Therapeutics stock surging today?

  • United Therapeutics stock surged 13.7% after Delaware court ruled Liquidia infringed on its patent.
  • Liquidia shares declined significantly, while United Therapeutics peaked at $556.20.
  • Victory strengthens Tyvaso franchise, reduces Liquidia's market access in PH-ILD indication.

More from Wednesday 30 September →